Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma
Patients who were refractory to enalidomide/dexamethasone were treated with the combination of lenalidomide, dexamethasone, and vorinostat. An objective response rate of 27% was seen, and therapy was well-tolerated. This represents a treatment option in heavily pretreated patients with myeloma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Elizabeth Bilotti, David H. Vesole, Laura McBride, Linda Schmidt, Zhijie Gao, Madiha Gilani, Ann McNeill, Urszula Bednarz, Joshua Richter, Anthony Mato, Thorsten Graef, David S. Siegel Tags: Original Study Source Type: research
More News: Hematology